China Cracks Down on Illegal Copies of Novo’s Weight-Loss Drug
China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
NJBIZ10h
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
Novo’s Wegovy Price Tag for Stroke Prevention Is Higher in US
Novo Nordisk A/S’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far ...
FierceBiotech1d
Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
NBC New York9d
Novo Nordisk weight-loss drug is effective for kids as young as 6, study shows
Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for ...
Benzinga.com1d
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk ...
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...